Company Analysis Medexus Pharmaceuticals Inc.
1. Summary
Advantages
- Price (1.26 $) is less than fair price (2.06 $)
- The stock's return over the last year (20.11%) is higher than the sector average (-34.04%).
Disadvantages
- Dividends (0%) are below the sector average (1.76%).
- Current debt level 32.04% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-0.8111%) is lower than the sector average (ROE=13.19%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Medexus Pharmaceuticals Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 19.7% | 4.6% | -0.1% |
| 90 days | 16.4% | -37.6% | 6.5% |
| 1 year | 20.1% | -34% | 25% |
MEDXF vs Sector: Medexus Pharmaceuticals Inc. has outperformed the "Healthcare" sector by 54.15% over the past year.
MEDXF vs Market: Medexus Pharmaceuticals Inc. has underperformed the market marginally by -4.86% over the past year.
Stable price: MEDXF is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: MEDXF with weekly volatility of 0.3867% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (1.26 $) is lower than the fair price (2.06 $).
Price significantly below the fair price: The current price (1.26 $) is 63.5% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (15.77) is lower than that of the sector as a whole (31.48).
P/E vs Market: The company's P/E (15.77) is lower than that of the market as a whole (46.91).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.02) is lower than that of the sector as a whole (3.36).
P/BV vs Market: The company's P/BV (1.02) is higher than that of the market as a whole (-8.98).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0.2726) is lower than that of the sector as a whole (3.24).
P/S vs Market: The company's P/S indicator (0.2726) is lower than that of the market as a whole (4.88).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (5.21) is lower than that of the sector as a whole (9.95).
EV/Ebitda vs Market: The company's EV/Ebitda (5.21) is lower than that of the market as a whole (25.28).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -19.31% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-19.31%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-52.93%).
5.4. ROE
ROE vs Sector: The company's ROE (-0.8111%) is lower than that of the sector as a whole (13.19%).
ROE vs Market: The company's ROE (-0.8111%) is higher than that of the market as a whole (-8.22%).
5.5. ROA
ROA vs Sector: The company's ROA (-0.135%) is lower than that of the sector as a whole (6.14%).
ROA vs Market: The company's ROA (-0.135%) is lower than that of the market as a whole (4.85%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.56%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (11.03%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.76%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
